Vaccine Trial "Put US Babies At Risk"

28 July 1996

The US National Vaccine Information Center and the Washington Office on Haiti are urging the US Food and Drug Administration to release all records, including raw data, on the high-dose Edmonston Zagreb measles vaccine experiments conducted by Kaiser Permanente, the Centers for Disease Control and Johns Hopkins University on babies in Los Angeles, Haiti, and more than a dozen other Third World countries.

The experimental vaccine given to babies as young as four months resulted in a higher than expected death rate, especially in girls. About 1,500 six-month-old black and Hispanic babies in inner-city Los Angeles were enrolled in the experiment before it was halted in 1991 after repeated warnings that babies were dying in greater numbers than expected up to three years after vaccination.

Informed Consent Regs Violated CDC chief David Satcher admitted last month that a National Institutes of Health investigation found that researchers violated informed consent regulations in the Los Angeles study. Parents were not told that the vaccine their babies got was experimental, and were not warned about immediate or long-term risks. Kaiser and the CDC deny that any Los Angeles infants were harmed, although one baby died from a bacterial infection they say was unrelated to the standard-dose EZ vaccination the baby received.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight